427-P: Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy among Commercially Insured Adults Aged <65 Years

While diabetes prevalence in U.S. adults has increased in the last three decades, less is known about trends in ocular complications of diabetes, particularly in adults aged

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2021-06, Vol.70 (Supplement_1)
Hauptverfasser:	LUNDEEN, ELIZABETH A., KIM, MINCHUL, REIN, DAVID B., WITTENBORN, JOHN, CAI, CINDY, SAADDINE, JINAN B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Diabetes mellitus (insulin dependent) Diabetic retinopathy Edema Injection Laser surgery Retina Retinal detachment Retinopathy Surgery Trends Vascular endothelial growth factor Vision
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue	Supplement_1
container_start_page
container_title	Diabetes (New York, N.Y.)
container_volume	70
creator	LUNDEEN, ELIZABETH A. KIM, MINCHUL REIN, DAVID B. WITTENBORN, JOHN CAI, CINDY SAADDINE, JINAN B.
description	While diabetes prevalence in U.S. adults has increased in the last three decades, less is known about trends in ocular complications of diabetes, particularly in adults aged
doi_str_mv	10.2337/db21-427-P
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2562266542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2562266542</sourcerecordid><originalsourceid>FETCH-LOGICAL-c632-bfcd9a0d87f5da4428b284deb92ae39fec924e7c2d1d5c66fcf008e48e55a47b3</originalsourceid><addsrcrecordid>eNpFkG9LwzAQh4MoOKdv_AQB3wnVNE3_iW_GnDqYOGSIvgrX5LJ1tOlMWmFfxM9rtwlycPeDe7iDh5DLkN3wKEpvdcHDQPA0mB-RQZhHeRDx9OOYDBgLeRCmeXpKzrxfM8aSvgbkZw_f0bnDb6jQKqRgNV04hLZG29LG0IcSCmxLRV9AdRU4OtFYw557L33Z2GCx2vFoS7v8p9_6bpsNtKsthbrpV-OmrtGpEqpqS6fWdw41Hemuaj0dLft8n8T0E8H5c3JioPJ48TeHZPE4WYyfg9nr03Q8mgUqiXhQGKVzYDpLTaxBCJ4VPBMai5wDRrlBlXOBqeI61LFKEqMMYxmKDOMYRFpEQ3J1OLtxzVeHvpXrpnO2_yh5nHCeJLHgPXV9oJRrvHdo5MaVNbitDJncaZc77bI3KefRL312dqY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2562266542</pqid></control><display><type>article</type><title>427-P: Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy among Commercially Insured Adults Aged <65 Years</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>LUNDEEN, ELIZABETH A. ; KIM, MINCHUL ; REIN, DAVID B. ; WITTENBORN, JOHN ; CAI, CINDY ; SAADDINE, JINAN B.</creator><creatorcontrib>LUNDEEN, ELIZABETH A. ; KIM, MINCHUL ; REIN, DAVID B. ; WITTENBORN, JOHN ; CAI, CINDY ; SAADDINE, JINAN B.</creatorcontrib><description>While diabetes prevalence in U.S. adults has increased in the last three decades, less is known about trends in ocular complications of diabetes, particularly in adults aged <65 years. We examined trends in prevalence and treatment of diabetic macular edema (DME) or vision-threatening diabetic retinopathy (DR) among commercially insured adults with diabetes. We analyzed claims from 2012 to 2018 using the IBM® MarketScan® Database, a national convenience sample of employer-sponsored health insurance. Analyses for each cross-sectional year included adults (18-64 years) with type 1 or 2 diabetes continuously enrolled for the calendar year (range: n=980,705 to n=1,715,815). Outcomes included the annual prevalence of those with ≥1 claim for: 1) DME or vision-threatening DR (severe non-proliferative DR or proliferative DR), 2) DME of any type, alone or with any stage of DR, and 3) treatment (anti-vascular endothelial growth factor [VEGF] injection, laser surgery/photocoagulation, vitrectomy, or retinal detachment repair). From 2012 to 2018, annual diabetes prevalence ranged from 7.3% to 7.8%. Annual prevalence of adults with diabetes who had ≥1 claim for DME or vision-threatening DR increased from 1.9% to 3.1% (Annual percent change [APC]: 0.23); any type of DME increased from 0.9% to 2.4% (APC: 0.29). Among those with DME or vision-threatening DR, annual prevalence of having ≥1 claim for treatment increased for anti-VEGF injection (21.9% to 31.2%; APC: 1.81) and decreased for laser surgery/photocoagulation (33.6% to 18.9%; APC: -2.65), vitrectomy (6.5% to 3.8%; APC: -0.48), and retinal detachment repair (3.9% to 2.9%; APC: -0.15). P-values for all trends were <0.01. From 2012 to 2018, among commercially insured adults aged <65 years, the annual prevalence of those with claims for DME or vision-threatening DR and DME of any type increased, coinciding with an increase in the use of anti-VEGF injection, a contemporary first-line treatment.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db21-427-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Diabetes ; Diabetes mellitus (insulin dependent) ; Diabetic retinopathy ; Edema ; Injection ; Laser surgery ; Retina ; Retinal detachment ; Retinopathy ; Surgery ; Trends ; Vascular endothelial growth factor ; Vision</subject><ispartof>Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>LUNDEEN, ELIZABETH A.</creatorcontrib><creatorcontrib>KIM, MINCHUL</creatorcontrib><creatorcontrib>REIN, DAVID B.</creatorcontrib><creatorcontrib>WITTENBORN, JOHN</creatorcontrib><creatorcontrib>CAI, CINDY</creatorcontrib><creatorcontrib>SAADDINE, JINAN B.</creatorcontrib><title>427-P: Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy among Commercially Insured Adults Aged <65 Years</title><title>Diabetes (New York, N.Y.)</title><description>While diabetes prevalence in U.S. adults has increased in the last three decades, less is known about trends in ocular complications of diabetes, particularly in adults aged <65 years. We examined trends in prevalence and treatment of diabetic macular edema (DME) or vision-threatening diabetic retinopathy (DR) among commercially insured adults with diabetes. We analyzed claims from 2012 to 2018 using the IBM® MarketScan® Database, a national convenience sample of employer-sponsored health insurance. Analyses for each cross-sectional year included adults (18-64 years) with type 1 or 2 diabetes continuously enrolled for the calendar year (range: n=980,705 to n=1,715,815). Outcomes included the annual prevalence of those with ≥1 claim for: 1) DME or vision-threatening DR (severe non-proliferative DR or proliferative DR), 2) DME of any type, alone or with any stage of DR, and 3) treatment (anti-vascular endothelial growth factor [VEGF] injection, laser surgery/photocoagulation, vitrectomy, or retinal detachment repair). From 2012 to 2018, annual diabetes prevalence ranged from 7.3% to 7.8%. Annual prevalence of adults with diabetes who had ≥1 claim for DME or vision-threatening DR increased from 1.9% to 3.1% (Annual percent change [APC]: 0.23); any type of DME increased from 0.9% to 2.4% (APC: 0.29). Among those with DME or vision-threatening DR, annual prevalence of having ≥1 claim for treatment increased for anti-VEGF injection (21.9% to 31.2%; APC: 1.81) and decreased for laser surgery/photocoagulation (33.6% to 18.9%; APC: -2.65), vitrectomy (6.5% to 3.8%; APC: -0.48), and retinal detachment repair (3.9% to 2.9%; APC: -0.15). P-values for all trends were <0.01. From 2012 to 2018, among commercially insured adults aged <65 years, the annual prevalence of those with claims for DME or vision-threatening DR and DME of any type increased, coinciding with an increase in the use of anti-VEGF injection, a contemporary first-line treatment.</description><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetic retinopathy</subject><subject>Edema</subject><subject>Injection</subject><subject>Laser surgery</subject><subject>Retina</subject><subject>Retinal detachment</subject><subject>Retinopathy</subject><subject>Surgery</subject><subject>Trends</subject><subject>Vascular endothelial growth factor</subject><subject>Vision</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpFkG9LwzAQh4MoOKdv_AQB3wnVNE3_iW_GnDqYOGSIvgrX5LJ1tOlMWmFfxM9rtwlycPeDe7iDh5DLkN3wKEpvdcHDQPA0mB-RQZhHeRDx9OOYDBgLeRCmeXpKzrxfM8aSvgbkZw_f0bnDb6jQKqRgNV04hLZG29LG0IcSCmxLRV9AdRU4OtFYw557L33Z2GCx2vFoS7v8p9_6bpsNtKsthbrpV-OmrtGpEqpqS6fWdw41Hemuaj0dLft8n8T0E8H5c3JioPJ48TeHZPE4WYyfg9nr03Q8mgUqiXhQGKVzYDpLTaxBCJ4VPBMai5wDRrlBlXOBqeI61LFKEqMMYxmKDOMYRFpEQ3J1OLtxzVeHvpXrpnO2_yh5nHCeJLHgPXV9oJRrvHdo5MaVNbitDJncaZc77bI3KefRL312dqY</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>LUNDEEN, ELIZABETH A.</creator><creator>KIM, MINCHUL</creator><creator>REIN, DAVID B.</creator><creator>WITTENBORN, JOHN</creator><creator>CAI, CINDY</creator><creator>SAADDINE, JINAN B.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20210601</creationdate><title>427-P: Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy among Commercially Insured Adults Aged <65 Years</title><author>LUNDEEN, ELIZABETH A. ; KIM, MINCHUL ; REIN, DAVID B. ; WITTENBORN, JOHN ; CAI, CINDY ; SAADDINE, JINAN B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c632-bfcd9a0d87f5da4428b284deb92ae39fec924e7c2d1d5c66fcf008e48e55a47b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetic retinopathy</topic><topic>Edema</topic><topic>Injection</topic><topic>Laser surgery</topic><topic>Retina</topic><topic>Retinal detachment</topic><topic>Retinopathy</topic><topic>Surgery</topic><topic>Trends</topic><topic>Vascular endothelial growth factor</topic><topic>Vision</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LUNDEEN, ELIZABETH A.</creatorcontrib><creatorcontrib>KIM, MINCHUL</creatorcontrib><creatorcontrib>REIN, DAVID B.</creatorcontrib><creatorcontrib>WITTENBORN, JOHN</creatorcontrib><creatorcontrib>CAI, CINDY</creatorcontrib><creatorcontrib>SAADDINE, JINAN B.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LUNDEEN, ELIZABETH A.</au><au>KIM, MINCHUL</au><au>REIN, DAVID B.</au><au>WITTENBORN, JOHN</au><au>CAI, CINDY</au><au>SAADDINE, JINAN B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>427-P: Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy among Commercially Insured Adults Aged <65 Years</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2021-06-01</date><risdate>2021</risdate><volume>70</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>While diabetes prevalence in U.S. adults has increased in the last three decades, less is known about trends in ocular complications of diabetes, particularly in adults aged <65 years. We examined trends in prevalence and treatment of diabetic macular edema (DME) or vision-threatening diabetic retinopathy (DR) among commercially insured adults with diabetes. We analyzed claims from 2012 to 2018 using the IBM® MarketScan® Database, a national convenience sample of employer-sponsored health insurance. Analyses for each cross-sectional year included adults (18-64 years) with type 1 or 2 diabetes continuously enrolled for the calendar year (range: n=980,705 to n=1,715,815). Outcomes included the annual prevalence of those with ≥1 claim for: 1) DME or vision-threatening DR (severe non-proliferative DR or proliferative DR), 2) DME of any type, alone or with any stage of DR, and 3) treatment (anti-vascular endothelial growth factor [VEGF] injection, laser surgery/photocoagulation, vitrectomy, or retinal detachment repair). From 2012 to 2018, annual diabetes prevalence ranged from 7.3% to 7.8%. Annual prevalence of adults with diabetes who had ≥1 claim for DME or vision-threatening DR increased from 1.9% to 3.1% (Annual percent change [APC]: 0.23); any type of DME increased from 0.9% to 2.4% (APC: 0.29). Among those with DME or vision-threatening DR, annual prevalence of having ≥1 claim for treatment increased for anti-VEGF injection (21.9% to 31.2%; APC: 1.81) and decreased for laser surgery/photocoagulation (33.6% to 18.9%; APC: -2.65), vitrectomy (6.5% to 3.8%; APC: -0.48), and retinal detachment repair (3.9% to 2.9%; APC: -0.15). P-values for all trends were <0.01. From 2012 to 2018, among commercially insured adults aged <65 years, the annual prevalence of those with claims for DME or vision-threatening DR and DME of any type increased, coinciding with an increase in the use of anti-VEGF injection, a contemporary first-line treatment.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db21-427-P</doi></addata></record>
fulltext	fulltext
identifier	ISSN: 0012-1797
ispartof	Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)
issn	0012-1797 1939-327X
language	eng
recordid	cdi_proquest_journals_2562266542
source	Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects	Diabetes Diabetes mellitus (insulin dependent) Diabetic retinopathy Edema Injection Laser surgery Retina Retinal detachment Retinopathy Surgery Trends Vascular endothelial growth factor Vision
title	427-P: Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy among Commercially Insured Adults Aged <65 Years
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A03%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=427-P:%20Prevalence%20and%20Treatment%20of%20Diabetic%20Macular%20Edema%20and%20Vision-Threatening%20Diabetic%20Retinopathy%20among%20Commercially%20Insured%20Adults%20Aged%20%3C65%20Years&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=LUNDEEN,%20ELIZABETH%20A.&rft.date=2021-06-01&rft.volume=70&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db21-427-P&rft_dat=%3Cproquest_cross%3E2562266542%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2562266542&rft_id=info:pmid/&rfr_iscdi=true